全文获取类型
收费全文 | 5364篇 |
免费 | 435篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 185篇 |
妇产科学 | 161篇 |
基础医学 | 790篇 |
口腔科学 | 110篇 |
临床医学 | 587篇 |
内科学 | 1155篇 |
皮肤病学 | 56篇 |
神经病学 | 402篇 |
特种医学 | 173篇 |
外科学 | 688篇 |
综合类 | 177篇 |
一般理论 | 1篇 |
预防医学 | 491篇 |
眼科学 | 43篇 |
药学 | 313篇 |
中国医学 | 5篇 |
肿瘤学 | 359篇 |
出版年
2023年 | 29篇 |
2022年 | 41篇 |
2021年 | 65篇 |
2020年 | 43篇 |
2019年 | 86篇 |
2018年 | 113篇 |
2017年 | 88篇 |
2016年 | 88篇 |
2015年 | 107篇 |
2014年 | 130篇 |
2013年 | 222篇 |
2012年 | 267篇 |
2011年 | 268篇 |
2010年 | 172篇 |
2009年 | 141篇 |
2008年 | 250篇 |
2007年 | 251篇 |
2006年 | 249篇 |
2005年 | 236篇 |
2004年 | 227篇 |
2003年 | 222篇 |
2002年 | 211篇 |
2001年 | 161篇 |
2000年 | 162篇 |
1999年 | 139篇 |
1998年 | 75篇 |
1997年 | 67篇 |
1996年 | 55篇 |
1995年 | 52篇 |
1994年 | 56篇 |
1993年 | 42篇 |
1992年 | 111篇 |
1991年 | 113篇 |
1990年 | 87篇 |
1989年 | 97篇 |
1988年 | 109篇 |
1987年 | 94篇 |
1986年 | 95篇 |
1985年 | 80篇 |
1984年 | 55篇 |
1983年 | 58篇 |
1982年 | 43篇 |
1981年 | 29篇 |
1980年 | 32篇 |
1979年 | 65篇 |
1978年 | 50篇 |
1976年 | 34篇 |
1974年 | 32篇 |
1970年 | 25篇 |
1966年 | 25篇 |
排序方式: 共有5811条查询结果,搜索用时 31 毫秒
91.
92.
93.
Stephen G Divers Sharon A Spencer Delicia Carey Elizabeth M Busby Mark D Hyatt Francisco Robert 《Journal of clinical oncology》2005,23(27):6664-6673
PURPOSE: This is a phase I/IIa study to assess tolerance of gemcitabine and paclitaxel with radiotherapy in locally advanced non-small-cell lung cancer after induction chemotherapy. PATIENTS AND METHODS: Fifty-seven patients with stage III non-small-cell lung cancer were treated with cisplatin 80 mg/m2 on days 1 and 22 and gemcitabine 1,250 mg/m2 on days 1, 8, 22, and 28. Chemoradiotherapy began on day 43 as follows: cohort 1 (n = 9), gemcitabine 300 mg/m2 and paclitaxel 35 mg/m2 weekly (except week 9); cohort 2 (n = 9), gemcitabine 150 mg/m2 and paclitaxel 35 mg/m2 weekly (except week 9); cohort 3 (n = 10) and the 25 phase IIa patients, gemcitabine 300 mg/m2 and paclitaxel 135 mg/m2 every 21 days. Patients were treated with three-dimensional thoracic radiotherapy concurrently to 60 Gy. RESULTS: Weekly chemotherapy resulted in grade 4 esophageal and grade 3 or higher pulmonary toxicities. Reduction in dose density (cohort 3) led to a tolerable toxicity profile and was chosen as the phase IIa regimen. The response rate to induction was 49%, with stable disease in 40% of the patients. The response rate after consolidation therapy was 75% (94% for weekly chemotherapy v 82% for every 3 weeks). Median survival was 23 months, and 3-year survival was 45% for eligible patients. Local relapse occurred in 20% of the patients. Performance status of more than 1 predicted for poor outcome, but baseline pulmonary function did not. Dosimetric parameters including V15, V20, V30 (percent lung volume receiving > or = 15, > or = 20, and > or = 30 Gy, respectively), and mean lung dose correlated with pulmonary toxicity. CONCLUSION: Additional investigation with the 3-week schedule is warranted in patients with a good performance status based on the safety profile and preliminary efficacy data observed in this study. 相似文献
94.
95.
96.
97.
98.
99.
J. L. Byrne M. J. Davies I. Willaing R. I. G. Holt M. E. Carey H. Daly S. Skovlund M. Peyrot 《Diabetic medicine》2017,34(8):1074-1083
100.
LC Diener JA Slyker C Gichuhi KA Tapia BA Richardson D Wamalwa C Farquhar J Overbaugh E Maleche-Obimbo G John-Stewart 《AIDS (London, England)》2012,26(15):1935-1941
OBJECTIVES:: Early infant HIV-1 diagnosis and treatment substantially improve survival. Where virologic HIV-1 testing is unavailable, integrated management of childhood illness (IMCI) clinical algorithms may be used for infant HIV-1 screening. We evaluated the performance of the 2008 WHO IMCI HIV algorithm in a cohort of HIV-exposed Kenyan infants. METHODS:: From 1999 to 2003, 444 infants had monthly clinical assessments and quarterly virologic HIV-1 testing. Using archived clinical data, IMCI sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated using virologic testing as a gold standard. Linear regression and survival analyses were used to determine the effect of age on IMCI performance and timing of diagnosis. RESULTS:: Overall IMCI sensitivity, specificity, PPV, and NPV value were 58, 87, 52, and 90%, respectively. Sensitivity (1.4%) and PPV (14%) were lowest at 1 month of age, when 81% of HIV infections already had occurred. Sensitivity increased with age (P?0.0001), but remained low throughout infancy (range 1.4-35%). Specificity (range 97-100%) was high at each time point and was not associated with age. Fifty-eight percent of HIV-1-infected infants (50 of 86) were eventually diagnosed by IMCI, and use of IMCI was estimated to delay diagnosis in HIV-infected infants by a median of 5.9 months (P?0.0001). CONCLUSION:: IMCI had low sensitivity during the first month of life, when the majority of HIV-1 infections had already occurred and initiation of treatment is most critical. Although sensitivity increased with age, the substantial delay in HIV-1 diagnosis using IMCI limits its utility in early infant HIV-1 diagnosis. 相似文献